To confirm the robustness of our proteomics quantification by SNOTRAP with MS analysis, we examined the levels of SNO-p62, SNO-C3, SNO-NRXN3, and SNO-PLD3 by immunoblot analysis following enrichment via SNOTRAP reagent.Indeed, in accord with our label-free SNOTRAP quantification by MS, these immunoblots demonstrated that the levels of S-nitrosylated p62, C3, NRXN3, and PLD3 were substantially increased in AD over the non-AD group (Fig. 4, E to H). This evidence concerns the gene NRXN3 and Alzheimer disease.